Dianthus Therapeutics (NASDAQ:DNTH) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Dianthus Therapeutics (NASDAQ:DNTH) released its earnings results on Tuesday. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05), FiscalAI reports. The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 25.73%.

Dianthus Therapeutics Stock Performance

DNTH traded down $4.88 during midday trading on Thursday, reaching $107.61. The company had a trading volume of 301,728 shares, compared to its average volume of 974,237. Dianthus Therapeutics has a 12-month low of $18.08 and a 12-month high of $114.55. The business has a 50-day moving average price of $94.02 and a two-hundred day moving average price of $79.98. The stock has a market cap of $5.88 billion, a PE ratio of -25.91 and a beta of 1.22.

Wall Street Analyst Weigh In

DNTH has been the topic of several research analyst reports. Truist Financial raised their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, HC Wainwright lifted their target price on Dianthus Therapeutics from $130.00 to $158.00 and gave the company a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.27.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 26,530 shares of Dianthus Therapeutics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at approximately $362,480. The trade was a 86.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Adam M. Veness sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $80.80, for a total value of $2,424,000.00. Following the completion of the transaction, the senior vice president owned 30,000 shares in the company, valued at approximately $2,424,000. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 87,779 shares of company stock worth $7,985,235 in the last quarter. Insiders own 3.02% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. Virtus Investment Advisers LLC increased its holdings in Dianthus Therapeutics by 7.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after acquiring an additional 416 shares during the period. Royal Bank of Canada grew its position in shares of Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock valued at $82,000 after purchasing an additional 542 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Dianthus Therapeutics by 4.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after purchasing an additional 618 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth $40,000. Finally, Deutsche Bank AG increased its holdings in shares of Dianthus Therapeutics by 9.3% in the fourth quarter. Deutsche Bank AG now owns 15,831 shares of the company’s stock worth $652,000 after purchasing an additional 1,343 shares during the period. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.